About Inflammatix

Tim Sweeney, MD, PhD

Dr. Sweeney helped invent the core Inflammatix technology and is a licensed physician and data scientist. He completed his MD/PhD at Duke University, and then spent time training in the general surgery residency program at Stanford University. While training as a surgeon, he became frustrated with the current diagnostic tools for infection. During his residency research years, he completed a postdoc MS in Biomedical Informatics, during which he worked with Dr. Khatri to identify a new way to diagnose infections based on ‘reading’ the immune system. Their work designing custom informatics algorithms for sifting through heterogeneous large datasets led to the core technology on which Inflammatix is based.

Oliver Liesenfeld, MD

Dr. Liesenfeld is an expert in the field of microbiology, infectious diseases and the host response. He has over 25 years of industry and academic experience in the diagnostics field, with a focus on molecular diagnostics and infectious diseases. He led Inflammatix’s clinical and scientific affairs teams as its chief medical officer from Jan 2018 to June 2024. Prior to his role at Inflammatix, as chief medical officer at Roche Molecular Diagnostics, he built a state-of-the-art medical department and led the company’s clinical science, medical affairs, clinical operations and biometrics functions. His team designed and executed numerous clinical trials to support regulatory approvals and commercialization of the company’s broad product portfolio, including the LightCycler® SeptiFast test for use in sepsis diagnosis.

Dr. Liesenfeld previously served as associate professor of Medical Microbiology and Infection Immunology at the Charite Medical School in Berlin, Germany, where his research focused on the immune response to infections. He holds an MD and a doctoral (Dr. med) degree from the Free University of Berlin, Germany and completed his residency in medical microbiology and infection epidemiology at the Charite Medical School, Berlin. He also completed a postdoctoral fellowship in the Division of Infectious Diseases and Geographic Medicine at Stanford University. Dr. Liesenfeld has authored more than 160 articles in peer-reviewed journals and more than 30 book chapters.

Sam Ajizian, MD

Dr. Sam Ajizian comes to Inflammatix as Chief Medical Officer after nearly 10 years at Medtronic, serving in CMO roles in the Acute Care & Monitoring businesses. He oversaw a $2Bn GAR global business serving over 115 million patients a year in over 70 countries. Sam served as the medical leader for business development and licensing activities, finding targets and bringing together cross functional teams to create agile and productive inorganic enhancements to the portfolio. He’s also a proven global leader in the medical device community, engaging key medical societies worldwide and driving adoption of products through research, guidelines, and education. He is a commercially facing CMO, energized by customers and how to best meet their needs leveraging the C suite with defined focus and production.

Jamie Lewis

Jamie Lewis, a seasoned commercial executive, leads Inflammatix’s commercial organization. With over 20 years in medical devices and software, she played a key role in Outset Medical’s IPO and held leadership positions at Intuitive Surgical during its rapid growth phase. Jamie also co-founded Matter Solutions, a platform enabling virtual mental and behavioral healthcare. She graduated from The Ohio State University, where she was a four-year starter and team captain for the basketball team, later becoming the first Ohio State player drafted by the WNBA’s Washington Mystics.

Laura Spencer Garth

In her role as General Counsel, Ms. Spencer Garth oversees the legal and compliance functions at Inflammatix. She has over 15 years of broad legal experience in corporate and litigation, with a particular focus in the medical device industry. Ms. Spencer Garth previously served as General Counsel of Stereotaxis (NYSE:STXS) and Veran Medical Technologies (acquired by Olympus in 2020). Prior to her in-house roles, Ms. Spencer Garth was a litigator and trial attorney at Dolley Law LLC and Bryan Cave Leighton Paisner LLP, where her practice areas included commercial litigation and labor & employment. She graduated with a BA in Political Science from Saint Louis University and holds a JD from Saint Louis University School of Law.

Paul Fleming, PhD

Dr. Fleming leads the engineering group at Inflammatix which encompasses systems, mechanical, electrical, software, manufacturing, and consumable engineering, as well as human-centered industrial design, digital design, and human factors, and usability engineering. Prior to Inflammatix, he served as the Director of Program Management and Site Operations for the diagnostic group at Ximedica, a product development company, and Chief Scientist at GenCell Biosystems. Dr. Fleming received his Ph.D. from the University of Limerick, Ireland, where his work focused on the development of an instrument for high throughput gene expression analysis directly from cells.

Jerry Ceglia

Jerry Ceglia leads the Operations and Finance Team bringing 25+ years of manufacturing and supply chain management experience to Inflammatix. He has served in start-up, emerging, and public companies effectively developing teams and infrastructure to provide innovative products for Class II & III medical instruments and consumables.

Jerry recently lead leadership positions at Sientra and St. Jude Medical with responsibilities spanning manufacturing organizations for both in-house and contract partners, Jerry has guided teams from early development through high volume production and commercialization. His extensive experience collaborating with global suppliers has resulted in shorter cycle time, inventory reduction and reduced product cost.

Jerry earned a Bachelor of Science from Notre Dame de Namur University and an MBA from Golden Gate University.